News Release 

Examining melanoma risk in patients treated with biologics for common inflammatory diseases

JAMA Dermatology

What The Study Did: This study combined the results of seven studies and compared the risk of melanoma among 34,000 patients treated with biologics and 135,000 patients treated with conventional systemic therapy for rheumatoid arthritis, psoriasis or inflammatory bowel disease.

Authors: Shamarke Esse, M.Res., of the University of Manchester in the United Kingdom, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamadermatol.2020.1300)

Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

###

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2020.1300?guestAccessKey=eb3d5444-37f1-4cd5-8a1d-eede84da416b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052020

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.